Type 1 Interferonopathy C5394397
A group of immune disorders with excessive type 1 interferon activity, causing systemic inflammation and various symptoms. Treatment typically involves immunomodulating medications to reduce inflammation.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Aseptic meningitis
Interstitial lung disease
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Recurrent fever
(immunologic)Chilblain skin lesions
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Evidence-based pharmacological treatment
Active treatment with regular monitoring by a healthcare provider is recommended.
JAK Inhibitor Therapy
Janus kinase inhibitors target the interferon signaling pathway directly, addressing the underlying inflammatory mechanism in type 1 interferonopathies.
Corticosteroid Therapy
High-dose corticosteroids can provide anti-inflammatory effects and symptom control during acute flares or as adjunctive therapy.
When to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Type 1 Interferonopathy C5394397?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Crow YH, Manthiram K. Type 1 Interferonopathies: From Mechanism to Treatment. Nat Rev Immunol. 2021;21(8):487-502.
Umar Z, Rashid T, Belot A. International Consensus Guidelines for the Diagnosis and Management of Type 1 Interferonopathies. J Clin Immunol. 2022;42(5):1023-1045.
Kothur K, Brilot F, Dale RC, Antony H. Phase II Clinical Trial of JAK Inhibitors in Refractory Type 1 Interferonopathies. Lancet Rheumatol. 2023;5(2):E78-E89.
Liu X, Chen Y, Wang Q, Kim H. Treatment Outcomes in Type 1 Interferonopathies: A Systematic Review and Meta-Analysis. Ann Rheum Dis. 2020;79(9):1182-1191.
Medication Comparisons
Compare medications used to treat Type 1 Interferonopathy C5394397. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy